p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting

被引:29
作者
Borre, M [1 ]
Stausbol-Gron, B
Overgaard, J
机构
[1] Aarhus Univ Hosp, Danish Canc Soc, Dept Expt Clin Oncol, Aarhus, Denmark
[2] Aarhus Univ Hosp, Danish Canc Soc, Dept Urol, Aarhus, Denmark
关键词
genes; p53; bcl-2; tumor markers; biological; prostatic neoplasms; prostate;
D O I
10.1016/S0022-5347(05)67288-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We describe the association of p53 nuclear protein accumulation with bcl-2 expression, tumor cell proliferation and clinical outcome in a prostate cancer population undergoing watchful waiting. Materials and Methods: Immunohistochemical staining for p53 was semiquantitatively scored in archival formalin fixed, paraffin embedded tumor tissue obtained at diagnosis in 221 patients with prostate cancer. At a median of 15 years followup was nearly complete. Eventually 57% of the patients died of prostate cancer. Results: p53 Immunohistochemical staining was heterogeneous but in all cases at least clusters of tumor cells had nuclear staining for p53. The percent of p53 immunoreactive tumor cells was scored as 0 to 4+ in p53 positive hot spots, p53 immunoreactivity correlated with clinical stage and histopathological grade (p = 0.003 and 0.009, respectively). When dichotomized into low (0% to 50%) and high (51% to 100%) immunoreactivity groups of 40 and 181 patients, respectively, p53 accumulation was significantly associated with disease specific survival in the study population overall (p <0.0001) and in the 125 with clinically localized disease (p = 0.0002). p53 Immunoreactivity was significantly (p <0.001) associated with the proliferation marker MIB-1 (median value 10.3, range 0 to 46.1) but insignificantly (p = 0.8) correlated with bcl-2 expression (52% positive). However, patients with combined favorable MIB-1 and bcl-2 status were stratified into significant (p = 0.02) prognostic groups by p53 immunohistochemical status. Multivariate analysis revealed that p53 immunoreactivity was a significant prognostic factor in patients with clinically localized prostate cancer (p <0.0001). Conclusions: p53 Nuclear protein accumulation detected by immunohistochemical study was an independent adverse prognostic factor in patients with prostate cancer undergoing watchful waiting.
引用
收藏
页码:716 / 721
页数:6
相关论文
共 53 条
[31]   Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer [J].
Jacobs, TW ;
Prioleau, JE ;
Stillman, IE ;
Schnitt, SJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (15) :1054-1059
[32]  
Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO
[33]  
2-O
[34]   APOPTOSIS - BASIC BIOLOGICAL PHENOMENON WITH WIDE-RANGING IMPLICATIONS IN TISSUE KINETICS [J].
KERR, JFR ;
WYLLIE, AH ;
CURRIE, AR .
BRITISH JOURNAL OF CANCER, 1972, 26 (04) :239-+
[35]   CANCER - P53, GUARDIAN OF THE GENOME [J].
LANE, DP .
NATURE, 1992, 358 (6381) :15-16
[36]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456
[37]   Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma [J].
Matsushima, H ;
Kitamura, T ;
Goto, T ;
Hosaka, Y ;
Homma, Y ;
Kawabe, K .
JOURNAL OF UROLOGY, 1997, 158 (06) :2278-2283
[38]   TRENDS IN PROSTATE-CANCER CARE IN THE UNITED-STATES, 1974-1990 - OBSERVATIONS FROM THE PATIENT-CARE EVALUATION STUDIES OF THE AMERICAN-COLLEGE-OF-SURGEONS-COMMISSION-ON-CANCER [J].
METTLIN, C ;
JONES, GW ;
MURPHY, GP .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (02) :83-91
[39]   Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer [J].
Moul, JW ;
Bettencourt, MC ;
Sesterhenn, IA ;
Mostofi, FK ;
McLeod, DG ;
Srivastava, S ;
Bauer, JJ .
SURGERY, 1996, 120 (02) :159-167
[40]   P53 PROTEIN ACCUMULATION AND GENE MUTATION IN THE PROGRESSION OF HUMAN PROSTATE CARCINOMA [J].
NAVONE, NM ;
TRONCOSO, P ;
PISTERS, LL ;
GOODROW, TL ;
PALMER, JL ;
NICHOLS, WW ;
VONESCHENBACH, AC ;
CONTI, CJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (20) :1657-1669